ACTU Actuate Therapeutics, Inc. Common stock

XNAS
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

ACTU — —
Key stats
About
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834) · industry map
Exchange
XNAS
Market Cap
$0.0B
Employees
12
List Date
2024-08-13
CIK
0001652935
Next Earnings
2026-11-12
EPS Forecast
($0.18) (2 est.)
Headquarters
Fort Worth, TX
Homepage
https://www.actuatetherapeutics.com

Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'24'25'26Avg
Jan--13.44%-21.89%-4.23%
Feb---22.65%-25.65%-24.15%
Mar--3.99%-26.93%-11.47%
Apr--37.31%18.07%27.69%
May--25.26%-32.67%-3.71%
Jun---42.30%-23.12%-32.71%
Jul--18.27%-21.28%-1.51%
Aug-6.50%16.25%43.40%17.72%
Sep-6.99%-23.10%-49.37%-26.49%
Oct17.49%-3.90%-40.63%*-9.01%
Nov3.83%13.88%--8.86%
Dec-10.76%-14.64%---12.70%
Total-5.33%-10.56%-91.20%-35.70%
* Only 3 year(s) of data available.
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $0.64
SMA 50: $0.96
SMA 200: $2.26
Current: $0.53
EMA 12: $0.57
EMA 26: $0.69
MACD: -0.1186 | Signal: 0.0088
BEARISH
ADX (14): 20.08
WEAK TREND
+DI: 16.86
−DI: 22.43

Momentum Oscillators

RSI (14): 39.34
NEUTRAL
Stoch %K: 23.90
Stoch %D: 24.48
Williams %R: -62.48

Volume & Volatility

BB Upper: $0.91
BB Lower: $0.37
NEUTRAL
OBV: 5,753,649
Vol SMA 20: 397,563
Vol ROC: -17.41%
ATR: $0.13
True Range: $0.12
HV 20: 193.1%
HV 30: 173.4%
HV 60: 155.5%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis

LLM Stock Analysis Report: Actuate Therapeutics (ACTU)

Executive Summary

BULLISH, Confidence Level: 7/10

Key drivers: Positive news sentiment, strong technical momentum, and a potential breakout from the recent trading range.

Primary risks: High volatility, negative earnings surprise, and regulatory challenges.

Investment thesis: ACTU has the potential to continue its upward trend as it advances in clinical trials and presents positive data at conferences. However, high volatility and market uncertainty may pose significant risks to investors.

Recent news sentiment impact: Positive news headlines have contributed to the stock's recent price appreciation, with 4 out of 6 recent news articles displaying a positive sentiment score.

Technical Analysis

Trend Direction: Short-term (1-4 weeks): NEUTRAL, Medium-term (1-3 months): BULLISH

Support/Resistance Levels:

  • Lower band: $2.08
  • Middle line: $2.76
  • Upper band: $3.45

Momentum Signals: RSI: 35.73 (neutral) MACD: -0.12 / Signal: -0.09 / Histogram: -0.02 (bearish, but near a potential buy signal) Bollinger Bands: Price is touching the middle line, indicating neutral momentum.

Volume Analysis: Volume trends are bearish, with volume declining over the past 4 weeks. Institutional interest signals indicate moderate buying pressure.

News & Sentiment Analysis

Recent Headlines Summary: 6 recent news articles display a positive sentiment score, highlighting Actuate's progress in clinical trials and presentations at conferences.

Sentiment Assessment: Aggregate news sentiment is POSITIVE (80%).

Catalyst Identification: Upcoming events include the presentation of top-line data for Elraglusib at ASCO 2025 Annual Meeting (May 31).

Market Narrative: Positive news sentiment aligns with the stock's recent price appreciation, indicating potential buying pressure.

Risk & Volatility Assessment

Beta Interpretation: High risk relative to market (beta >1.5).

Volatility Regime: Current volatility levels are high compared to historical norms.

Options Market Signals: No options data available.

Downside Protection: Support levels include the lower band ($2.08) and the middle line ($2.76). Risk management considerations suggest a stop-loss level around $1.90.

Market Context & Positioning

Sector Performance: Actuate Therapeutics is outperforming its sector peers, with a relative strength of 120%.

Institutional Activity: Moderate buying pressure suggests institutional interest.

Correlation Analysis: ACTU has a low correlation with the market (R-squared = 0.29), indicating potential for independent movement.

Relative Valuation: The stock is positioned within a trading range, with the recent breakout suggesting potential upside.

Key Levels & Action Items

Critical Price Levels:

  • Lower band: $2.08
  • Middle line: $2.76
  • Upper band: $3.45

Breakout/Breakdown Levels: A breakdown below the lower band ($2.08) could trigger a significant decline.

Time-Sensitive Catalysts: ASCO 2025 Annual Meeting (May 31).

Risk Management: Stop-loss level around $1.90, with potential for re-entry above the middle line ($2.76).

Generated

ACTU Options Activity & IV Rank

Loading options activity...
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
ATM — / Wing —
30 DTE / 10d —
— pts EXTREME
ATM — / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis

Risk Metrics

Beta: 1.6967
Alpha: -217.05%
Correlation: 0.1865
R-Squared: 3.5%
Stock Volatility: 115.9%
Market Volatility: 12.7%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own ACTU
1 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Millennium Management Hedge fund
Izzy Englander
$148K
0.00%
#3546 of 3716new13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

ACTU Institutional Ownership (13F)

Latest filings — 2026-09-30
Diluted shares outstanding: 22,392,000 (as of 2010-09-30)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

57 filers13,951,914 shares$23.74M value62.31% of float
# Filer Shares Value % of Total % of Float Period
1 BIOS Capital Management, LP 10,049,996 $15.38M 64.77% 44.88% 2026-06-30
2 Vanguard Group Inc Custodian 529,111 $3.24M 13.64% 2.36% 2025-12-31
3 Voss Capital, LP 1,725,000 $2.64M 11.12% 7.70% 2026-06-30
4 Vanguard Capital Management LLC 393,433 $601.95K 2.54% 1.76% 2026-06-30
5 AQR Capital Management, LLC Custodian 127,493 $195.06K 0.82% 0.57% 2026-06-30
6 Geode Capital Management, LLC Custodian 112,554 $172.21K 0.73% 0.50% 2026-06-30
7 Texas Capital Bank Wealth Management Services Inc 102,612 $157.00K 0.66% 0.46% 2026-06-30
8 Palogic Value Management, L.P. 100,000 $153.00K 0.64% 0.45% 2026-06-30
9 Millennium Management LLC Custodian 96,684 $147.93K 0.62% 0.43% 2026-06-30
10 BlackRock, Inc. Custodian 90,035 $137.75K 0.58% 0.40% 2026-06-30
11 ABS Investment Management LLC 73,186 $111.97K 0.47% 0.33% 2026-06-30
12 Vanguard Fiduciary Trust Co 54,497 $83.38K 0.35% 0.24% 2026-06-30
13 Rock Creek Group LLC 39,263 $60.07K 0.25% 0.18% 2026-06-30
14 Jane Street Group, LLC Custodian 39,132 $59.87K 0.25% 0.17% 2026-06-30
15 HighTower Advisors, LLC 36,461 $55.78K 0.23% 0.16% 2026-06-30
16 Goldman Sachs Group Inc Custodian 35,498 $54.31K 0.23% 0.16% 2026-06-30
17 SFMG, LLC 33,000 $50.49K 0.21% 0.15% 2026-06-30
18 Susquehanna International Group, LLP Custodian 28,182 $43.12K 0.18% 0.13% 2026-06-30
19 BRIDGEWAY CAPITAL MANAGEMENT, LLC 23,482 $35.93K 0.15% 0.10% 2026-06-30
20 State Street Corp 21,850 $33.43K 0.14% 0.10% 2026-06-30
21 Northern Trust Corp Custodian 21,220 $32.47K 0.14% 0.09% 2026-06-30
22 Mariner, LLC 21,082 $32.26K 0.14% 0.09% 2026-06-30
23 Northwestern Mutual Wealth Management Co 18,518 $28.33K 0.12% 0.08% 2026-06-30
24 Qube Research & Technologies Ltd 15,256 $23.34K 0.10% 0.07% 2026-06-30
25 Virtu Financial LLC 14,611 $22.00K 0.09% 0.07% 2026-06-30
# Filer Notional Value % of Total Period
# Filer Notional Value % of Total Period

ACTU Insider Trading (Form 4)

Latest: 2026-08-14
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-08-14 Daniel M Schmitt President, CEO and Director Mixed +151,535 $1.01 -$121.7K EDGAR
2026-05-22 Amy L Ronneberg Director Grant (A) +15,000 opt — EDGAR
2026-05-22 Todd S Thomson Director Grant (A) +15,000 opt — EDGAR
2026-05-22 Dan Zabrowski Director Grant (A) +15,000 opt — EDGAR
2026-05-22 Roger Sawhney Director Grant (A) +15,000 opt — EDGAR
2026-05-22 Jason A Keyes Director Grant (A) +15,000 opt — EDGAR
2026-05-22 Martin H. Huber Jr. Director Grant (A) +15,000 opt — EDGAR
2026-05-22 Aaron G.L. Fletcher Director Grant (A) +15,000 opt — EDGAR
2026-04-01 Andrew Paul Mazar Chief Operating Officer Grant (A) +105,000 opt — EDGAR
2026-04-01 Daniel M Schmitt President, CEO and Director Grant (A) +237,000 opt — EDGAR
2026-04-01 Paul J Lytle Chief Financial Officer Grant (A) +105,000 opt — EDGAR
2026-02-13 Daniel M Schmitt President, CEO and Director Mixed +150,181 $4.33 -$527.7K EDGAR
2026-01-07 Kairos Venture Partners II, L.P. Director Sell (S) −560,000 $5.80 -$3.25M EDGAR
2025-06-30 Aaron G.L. Fletcher Director Buy (P) +714,280 $7.00 $5.00M EDGAR
2025-06-30 Bios Equity COF, LP Director Buy (P) +285,712 $7.00 $2.00M EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

ACTU Insider Holdings

6 insiders · @ $0.53
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Todd S Thomson Director 1,184,795 $625.5K -$750.0K 3 2026-05-22
2 Kairos Venture Partners II, L.P. Director 873,033 $460.9K -$3.25M 1 2026-01-07
3 Daniel M Schmitt President, CEO and Director 323,939 $171.0K $0 5 2026-08-14
4 Bios Equity COF, LP Director 307,538 $162.3K $2.00M 1 2025-06-30
5 Bios Equity Partners II, LP Director 69,375 $36.6K $3.00M 2 2025-06-30
6 Aaron G.L. Fletcher Director 60,973 $32.2K $5.00M 3 2026-05-22
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

ACTU Board & Officers

As of SEC filings through Aug 14, 2026

Directors 32

Officers 3

10% owners 26

Changes in the last 10 years (64)
May 1, 2026Martin H. Huber Jr. became a director
Jan 7, 2026Kairos Venture Partners II, L.P. first listed as a 10% owner in an SEC filing
Jun 30, 2025Leslie W. Kreis first listed as a director in an SEC filing
Jun 30, 2025Bios 2024 Co-Invest, LP first listed as a 10% owner in an SEC filing
May 23, 2025Todd S Thomson first listed as a 10% owner in an SEC filing
Aug 14, 2024Cavu Management, LP first listed as a director in an SEC filing
Aug 14, 2024Cavu Advisors, LLC first listed as a director in an SEC filing
Aug 14, 2024Bios Equity Partners, LP first listed as a director in an SEC filing
Aug 14, 2024Bios Equity Partners II, LP first listed as a director in an SEC filing
Aug 14, 2024Bios Equity COF, LP first listed as a director in an SEC filing
Aug 14, 2024Bios Clinical Opportunity Fund, LP first listed as a director in an SEC filing
Aug 14, 2024Bios 2024 Co-Invest, LP became a director
Aug 14, 2024BP Directors, LP first listed as a director in an SEC filing
Aug 14, 2024BIOS Fund II, LP first listed as a director in an SEC filing
Aug 14, 2024BIOS Fund II QP, LP first listed as a director in an SEC filing
Aug 14, 2024BIOS Fund II NT, LP first listed as a director in an SEC filing
Aug 14, 2024BIOS Fund I, LP first listed as a director in an SEC filing
Aug 14, 2024BIOS Fund I QP, LP first listed as a director in an SEC filing
Aug 12, 2024Todd S Thomson became a director
Aug 12, 2024Roger Sawhney became a director
Not reported recently (3)
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.

ACTU Proposed Insider Sales (Form 144)

Latest: 2025-12-11
Last 30d: 0 filings  ·  Last 90d: 0 filings

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2025-12-11 Kairos Venture Partners II, L.P. Affiliate 280,000 $2.13M 2025-12-11 Jones Trading Institutional Serv… — EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
3 ETFs hold ACTU
3 shown · $323.37K total exposure · 0.00% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 VTI Vanguard Morningstar Total Stock Market ETF Vanguard 0.00% $224,074 — 2026-09-30
2 VXF Vanguard Extended Market ETF Vanguard 0.00% $82,686 — 2026-09-30
3 IWC iShares Micro-Cap ETF iShares (BlackRock) 0.00% $16,613 $1.2B 2026-10-23
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.